Stockreport

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress [Yahoo! Finance]

Revolution Medicines, Inc.  (RVMD) 
PDF First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging safety, tolerability and antitumor activity in patients with PDAC harbo [Read more]